CLGN COLLPLANT BIOTECHNOLOGIES LT revenue, earnings and financials
For the quarter ended June 30, 2025, COLLPLANT BIOTECHNOLOGIES LT reported revenue of $179K (down 28.1% from a year earlier), net income of −$3.35M and diluted EPS of $0.28; for the fiscal year ended December 2025 revenue was $2.37M, up 360.4% on the year before.
CLGN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $2.37M, gross profit $1.54M, operating income −$11.5M, net income −$11.5M (margin -484.6%), EPS −$0.94
- Fiscal year ended Dec 2024: revenue $515K, gross profit −$1.11M, operating income −$17.3M, net income −$16.6M (margin -3225.0%), EPS −$1.45
- Fiscal year ended Dec 2023: revenue $11.0M, gross profit $8.97M, operating income −$7.51M, net income −$7.02M (margin -64.0%), EPS −$0.62
- Fiscal year ended Dec 2022: revenue $299K, gross profit −$101K, operating income −$17.1M, net income −$16.9M (margin -5660.5%), EPS −$1.53
- Fiscal year ended Dec 2021: revenue $15.6M, gross profit $13.6M, operating income $65.0K, net income $237K (margin 1.5%), EPS $0.02
CLGN quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue $179K (down 28.1% year over year), net income −$3.35M, EPS $0.28
- Quarter ended Jun 30, 2024: revenue $249K (down 97.6% year over year), net income −$4.21M, EPS $0.37
- Quarter ended Jun 30, 2023: revenue $10.2M (up 15330.3% year over year), net income $5.76M, EPS $0.49
- Quarter ended Jun 30, 2022: revenue $66.0K (down 90.4% year over year), net income −$4.29M, EPS −$0.39
- Quarter ended Jun 30, 2021: revenue $691K, net income −$3.04M, EPS −$0.30
CLGN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$9.42M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$14.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$2.76M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$13.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $2.50M, share buybacks n/a
CLGN balance sheet
- Dec 31, 2025: cash $5.59M, total assets $10.8M, total liabilities $4.70M, shareholders' equity $6.08M
- Jun 30, 2025: cash $11.4M, total assets $17.4M, total liabilities $4.93M, shareholders' equity $12.5M
- Dec 31, 2024: cash $11.9M, total assets $18.7M, total liabilities $5.25M, shareholders' equity $13.5M
- Jun 30, 2024: cash $18.9M, total assets $26.6M, total liabilities $5.84M, shareholders' equity $20.7M
- Dec 31, 2023: cash $26.7M, total assets $34.1M, total liabilities $5.79M, shareholders' equity $28.3M
- Jun 30, 2023: cash $22.3M, total assets $41.6M, total liabilities $5.53M, shareholders' equity $36.0M
- Dec 31, 2022: cash $29.7M, total assets $37.8M, total liabilities $5.49M, shareholders' equity $32.3M
- Jun 30, 2022: cash $36.3M, total assets $44.4M, total liabilities $4.91M, shareholders' equity $39.5M
What is CLGN's revenue?
COLLPLANT BIOTECHNOLOGIES LT reported $2.37M of revenue for the fiscal year ended December 2025.
Is CLGN profitable?
No. COLLPLANT BIOTECHNOLOGIES LT lost $11.5M in its latest fiscal year.